IP Library Granted Patent US 8,268,853
Granted Patent B2
US 8,268,853 · App. 12/823,969 · Granted Sep 18, 2012

3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,853
App. No.
12/823,969
Granted
Sep 18, 2012
Kind
B2
Abstract

Compounds of formula (I) are useful in treating conditions or disorders ameliorated by α4β2 positive allosteric modulators. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

Claims (27)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein

L is a bond, CH 2 , or NR 7 ;

R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from hydrogen, halogen, and methoxy, wherein at least one of R 1 , R 2 , R 3 , R 4 and R 5 is halogen and at least one of R 1 , R 2 , R 3 , R 4 and R 5 is methoxy;

R 6 is hydrogen or methyl; and

R 7 is hydrogen or alkyl.

2. The compound according to claim 1 of formula (I), wherein R 6 is hydrogen.

3. The compound according to claim 1 of formula (I), wherein R 6 is methyl.

4. The compound according to claim 1 of formula (I), wherein L is a bond.

5. The compound according to claim 1 of formula (I), wherein L is CH 2 .

6. The compound according to claim 1 of formula (I), wherein L is NR 7 .

7. The compound according to claim 1 of formula (I), wherein L is a bond and R 6 is hydrogen.

8. The compound according to claim 1 of formula (I), wherein L is a bond and R 6 is methyl.

9. The compound according to claim 1 of formula (I), wherein L is a CH 2 and R 6 is methyl.

10. The compound according to claim 1 of formula (I), wherein L is NR 7 , wherein R 7 is hydrogen, and R 6 is methyl.

11. The compound of claim 1 , selected from the group consisting of:

3-(4-fluoro-3-methoxybenzoyl)-3,9-diazaspiro[5.5]undecane;

3-(4-fluoro-3-methoxybenzoyl)-9-methyl-3,9-diazaspiro[5.5]undecane;

3-(3-fluoro-4-methoxybenzoyl)-9-methyl-3,9-diazaspiro[5.5]undecane;

3-(3-chloro-4-methoxybenzoyl)-9-methyl-3,9-diazaspiro[5.5]undecane;

3-(3,5-dichloro-4-methoxybenzoyl)-9-methyl-3,9-diazaspiro[5.5]undecane;

3-(3-chloro-4,5-dimethoxybenzoyl)-9-methyl-3,9-diazaspiro[5.5]undecane;

N-(3-fluoro-4-methoxyphenyl)-9-methyl-3,9-diazaspiro[5.5]undecane-3-carboxamide;

N-(3-chloro-4-methoxyphenyl)-9-methyl-3,9-diazaspiro[5.5]undecane-3-carboxamide;

N-(5-chloro-2,4-dimethoxyphenyl)-9-methyl-3,9-diazaspiro[5.5]undecane-3-carboxamide; and

3-[(3-fluoro-4-methoxyphenyl)acetyl]-9-methyl-3,9-diazaspiro[5.5]undecane.

12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a salt thereof, in a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030237/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: SCHRIMPF, MICHAEL R.; NERSESIAN, DIANA L.; LEE, CHIH-HUNG; FAGHIH, RAMIN; GFESSER, GREGORY A.
To: ABBOTT LABORATORIES
Reel/Frame 024940/0386 →